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Is Carcinogenesis Fundamentally Adversarial –
Confrontational or Physiologic–Adaptive?
Emmanuel Farber
The dominant dogma concerning the essential cellular changes during preneoplasia and precancer considers these as
abnormal or foreign that evoke a basic ‘‘host-parasite’’ response. An alternative view of how cancer develops, here briefly
outlined, views the early and intermediate cellular changes as essentially physiologic and adaptive. This different concept
introduces clonal adaptation as a basic response to many genotoxic carcinogenic stimuli including chemicals, radiations,
and some viruses. The evidence in support of this new view of the carcinogenic process is summarized. J Invest Dermatol
100:251S–253S, 1993
Physicians and other biologists, as scientists, frequently have an innate
mistrust of philosophical generalizations in the analysis of any biologic
process, including disease processes. Yet, we all know that without some
‘‘guiding principles,’’ research in disease becomes truly a meaningless
operation that can hardly be designated as science.
Cancer research is no exception. Many ideas have been proposed
over the past 150 years or so that purport to explain the ‘‘hows and
whys’’ of cancer. This is particularly prevalent in this area because this is
one of the few scientific fields where not knowing is not much of a barrier
to theoretical formulations.
CONCEPTS OF CANCER AND CANCER DEVELOPMENT
All living forms have evolved in a largely unfriendly or even hostile
environment in which protective responses to many different forms of
potential injury or harm have been essential for survival and reproduc-
tion. The acquisition of mechanisms for many different adaptive
responses could be considered to be just as important to survival and
to perpetuation of the species as the development of the essential
pathways for the basic physiologic needs, such as energy and the
synthesis of the small and large molecules that are the essential
components of the pathways. It is widely recognized that a variety of
physiologic-adaptive responses to environmental influences, such as
varying altitudes, hormonal modulations, as well as aging, are funda-
mental properties of living organisms. In addition, the vast array of
xenobiotic chemicals (including the many different organic chemicals in
foods) and microorganisms, as well as irradiation to which all living
organisms have been exposed since the early forms evolved some 2–3
billion years ago, would require the development of versatile protective
systems. Such protective or adaptive mechanisms are known to exist
throughout the whole spectrum of living forms, from single-cell
microorganisms to differentiated eukaryotes.
Because disease processes are largely expressions of how living
organisms react and respond to perturbations in the external and internal
environments, adaptive or protective responses and their modulations
and mechanisms are of the greatest concern in fundamental studies of
disease pathogenesis.
Fundamentally, there have been two major concepts that have guided
the majority of cancer researchers. Scientists and clinicians have
discussed for decades the issue of whether cancer is fundamentally a
‘‘genetic’’ or, better, a ‘‘genomic’’ disease or whether it is more likely to
be an ‘‘epigenetic process.’’ A large component of the latter could be
considered under the rubric of ‘‘adaptive responses.’’
During the past 20 years, the evidence in favor of an interaction of
carcinogenic genotoxic chemicals, irradiation, and DNA and RNA
viruses with the genome of target cells is so overwhelming that one
cannot seriously consider cancer development as a biologic process not
involving the genome as a critical component. Even considerations of
differentiation and cancer, a most interesting area, cannot deny genomic
changes as crucial to the carcinogenic process. Mutations, gene
rearrangements, and translocations and/or other forms of genomic
disorganization are common accompaniments of cancer.
The only possible exception, and one that remains to be studied in
much more cellular and molecular detail, is the increasing number of
‘‘non-genotoxic’’ chemicals, such as several hypolipidemic drugs and
anti-allergic drugs and some halogenated hydrocarbons used in industry
and agriculture. These are unquestionably carcinogenic yet do not seem
to show either the interactions with DNA, including mutagenicity, in
many prokaryotes and eukaryotes, or the well-delineated initiation steps
seen readily with the genotoxic carcinogens; however, because we do
not know the chemical basis for the initiation of chemical carcinogenesis
in any system, judgment as to the place of non-mutagenic systems in the
spectrum of carcinogenesis remains open. In addition, as the steps and
mechanisms during cancer development are studied in greater depth,
phenomena become apparent that suggest that adaptive reactions and
responses may play important or even critical roles in the process of
carcinogenesis.
Given the acceptance of some types of genomic change in many
known instances of cancer development, we are faced with a much more
important, as well as practical, consideration. Do the cells with altered
genomes behave essentially in a confrontational role in the host to create
an adversarial situation or do the selective and other important host
processes exercise major options and limits to the type of initiated cell
allowed to persist and grow? In other words, is the process of
carcinogenesis fundamentally an adversarial one (i.e., an abnormal cell
in a vulnerable host), or is it more in the nature of a physiologic selection
or differentiation, a form of metaplasia that has survival value for the host
as an adaptive phenomenon?
Adversarial – Confrontational The overwhelming view of both scientists
and clinicians is biased toward the first possibility–adversarial. This view
naturally considers the appropriate approach to cancer therapy as one of
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creating more efficient ways to kill the abnormal cells. This approach is
not only used for cancer but also for cancer precursors. Included of
course are the older and newer approaches to the immunologic control
of cancer. Because the cancer cells and their precursors are assumed
to be ‘‘abnormal’’ in that they are foreign to the host, it is natural that
immunologic approaches be encouraged, including the use of killer
lymphocytes and other categories of lymphocytes and cytotoxic
macrophages.
This dominant monolithic view of cancer cells and their precursors in the
carcinogenic process is a natural outcome of the nature of the emphasis in
cancer research. Because a major goal today of most cancer research is the
cure of end-stage cancer, and because some cancers can be initiated by an
increasing number of known ‘‘carcinogens,’’ it is to be expected that the
focus in cancer research should be on the ‘‘end,’’ the out-and-out cancer and
its behavior and, to a lesser degree, on the beginning. The very long process
whereby cancer develops, the carcinogenic process, is of necessity not
emphasized because it is only visible and easily amenable to treatment in
few types of cancer in humans.
Given (a) the genotoxic nature of many chemical carcinogens,
radiations, DNA viruses and perhaps RNA viruses, (b) the wide range of
genomic alterations readily induced by many of these agents, (c) the
obvious ‘‘physiologically abnormal’’ behavior of cancer cells and their
progeny, (d) the many genomic alterations seen in most cancers, (e) the
hereditary behavior of the cancer phenotype, (f) the genomic disorgani-
zation so common in most if not all cancers, and (g) the extreme diversity
and heterogeneity of cancers even of a single cell type, it is only natural
that cancer should be viewed as an ‘‘abnormal’’ or ‘‘foreign’’ cell that
must be eradicated. Thus, the ‘‘adversarial’’ or ‘‘confrontational’’ view of
cancer and cancer development has considerable justification.
Physiologic-Adaptive Because the evidence in support of the adversarial –
confrontational concept of cancer development is considerable, why should
an alternative view, an adaptive one, be given serious consideration? The
scientific justification for such a different view of the nature of the responses
of the living eukaryote to carcinogens has been discussed periodically [1–6]
and therefore is only summarized here.
What evidence is there for a ‘‘physiologic-adaptive’’ view for
carcinogenesis?
1. The earliest new cell populations that appear after initiation show a
common phenotype in the liver, regardless of the chemical nature
and the pattern of metabolism of the initiating chemical carcinogen
[4,7].
2. This constitutive new phenotype in the rare, altered hepatocyte is
very similar to that induced reversibly in the whole liver by
butylated hydroxyanisole (BHA), butylated hydroxy toluene (BHT),
lead nitrate, or an interferon [5,8]. Thus, the new phenoltype in the
rare, altered cell is not abnormal but can be ‘‘turned on’’
temporarily by other environmental perturbations. It consists of
many enzymes and proteins.
3. A seemingly similar phenotype is induced by exposure of liver
epithelial cell cultures to two retroviral oncogenes and a chemical
carcinogen in vitro [9,10].
4. The new cell populations that are induced by carcinogens clearly
represent a new pattern of differentiation with at least two biologic
options –differentiation to the mature adult liver as the major option and
persistence with slow progression to cancer as a minor one [4,11]. The
differentiation option is clearly genetically programmed because it
occurs spontaneously and involves many enzymes and proteins, cell
structure, cell-to-cell organization, and the blood supply, as well as other
physiologic parameters.
5. The clonal expansion during promotion of carcinogen-in duced rare
hepatocytes with a resistance phenotype, producing a liver with
many nodules of resistant hepatocytes, is associated with an obvious
protective role for the liver and for the host against cytotoxic and
lethal effects of some xenobiotics, including carcinogens [4,12–18].
6. Hepatocyte proliferation in the putative pre-cancerous expanded
clones, the persistent hepatocyte nodules, is almost balanced by
hepatocyte cell loss in these nodules until late in the carcinogenic
process when unequivocal cancer appears [19–22]. Until malignant
neoplastic changes appear, the nodules grow very slowly. The
balance between cell proliferation and cell loss is a physiologic
feature of the normal liver when the liver is exposed to primary
mitogens that induce hyperplasia over and above the normal
physiologic size of that liver [22–24]. Thus, the nodules retain a
major physiologic control for cell proliferation until very late in the
process of cancer development.
7. There appears to be no immune response to the new cell population
until very late in the carcinogenic process, with the final progression to
cancer [25]. The late immunologic responses might be related to the
common occurrence in virtually all cancers but especially those of
epithelial origin (carcinomas), of cell death with inflammation and the
release of probably hundreds of cell constituents that normally never
leave the cell until it dies.
In view of the many different cellular and tissue biologic processes
that go to make up the long, complicated carcinogenic process, it seems
highly probable that physiologic-adaptive and adversarial-confronta-
tional components are both present at different times and to different
degrees. It appears attractive to consider the early and intermediate steps
in the carcinogenic process as mainly physiologic – adaptive, with the
stages of frank malignancy with increasing progression showing more
adversarial – physiologic properties.
The very early initial interactions of mutagenic chemical carcinogens,
irradiation, and viruses with DNA would obviously prejudice most of us
to consider the ‘‘adversarial, abnormal’’ view as the appropriate one. Yet,
I cannot overemphasize the unusually common nature of the earliest
altered, rare cells that appear during carcinogenesis, their unusually
bland nature, and their spontaneous differentiation to normal-appearing
adult liver. In my opinion, there is virtually no evidence to support the
view that the rare, altered cells appearing after initiation are in any way
‘‘abnormal’’ in their behavior. The finding of structural alterations in
some genes after initiation does not prove by any stretch of the
imagination that they are playing any role as determinants and that the
new rare cell is biologically a mutant.
Other Systems Although this view of cancer development is based
largely on the analysis of liver cell cancer development in the rat, there
are many similarities to the processes occurring in the skin of the mouse,
the urinary bladder of the rat, and the development of malignant
melanoma in the human. The studies of Wallace Clark and his
collaborators over the years have shown a remarkable resemblance
between the patterns of biologic behavior between some of the
intermediate cell populations of the process in the human skin and that
in the rat liver [26]. Such similarities and analogies remain as challenges
to the further elucidation of the basic sequence(s) of cellular and
molecular changes that are fundamental to our understanding of how
malignant melanoma and other malignant neoplasms develop.
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